Artifactually low hemoglobin A1c caused by use of dapsone

Endocrine Practice

Volumn 8, Issue 5, 2002, Pages 370-372

  Albright, Eric S ^a   Ovalle, Fernando ^a   Bell, David S H ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE; FRUCTOSAMINE; GLUCOSE; HEMOGLOBIN A1C; METHEMOGLOBIN; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CASE REPORT; DEPRESSION; DERMATITIS HERPETIFORMIS; DIAGNOSTIC ERROR; ERYTHROCYTE LIFESPAN; FEMALE; FRUCTOSAMINE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HASHIMOTO DISEASE; HEMOLYTIC ANEMIA; HUMAN; METHEMOGLOBINEMIA; SPINE DISEASE; STRESS INCONTINENCE; BLOOD; INSULIN DEPENDENT DIABETES MELLITUS; LABORATORY DIAGNOSIS;

ADULT; BLOOD GLUCOSE; DAPSONE; DIABETES MELLITUS, TYPE 1; FALSE NEGATIVE REACTIONS; FEMALE; FRUCTOSAMINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS;

EID: 0036737138     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.8.5.370     Document Type: Article

References (16)

1. Baynes KCR, McIntosh C, Feher MD. Artifactually low glycated hemoglobin is a potential pitfall in diabetes management: consider congenital hemolytic anemias. Practical Diabetes Int. 2001; 18:103-106.
2. Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 1984;310:341-346.
3. Ceriello A, Giugliano D, Quatraro A, Donzella C, Dipalo G, Lefebvre PJ. Vitamin E reduction of protein glycosylation in diabetes: new prospect for prevention of diabetic complications? Diabetes Care. 1991;14:68-72.
4. Davie SJ, Gould BJ, Yudkin JS. Effect of vitamin C on glycosylation of proteins. Diabetes. 1992;41:167-173.
5. Thivolet C, Goujon R, Vassy V, Revol A, Tourniaire J. Interference of elevated fetal hemoglobin on HbA1c measurements in adult type I diabetic patient [letter]. Diabetes Care. 1991;14:1108.
6. Wallach J. Interpretation of Diagnostic Tests. 7th ed. Philadelphia: Lippincott-Williams & Wilkins, 2000: 610-611.
7. Meyers WM. Leprosy. Dermatol Clin. 1992;10:73-96.
8. Lacy C. Drug Information Handbook. Hudson (Cleveland), OH: Lexi-Comp, Inc, 2001.
9. Peterson CM, Ahkavan M, Fernandez-Soto ML, Rowell C, Scott BK, Peterson KP. Dapsone at onset of diabetes lowers glycated hemoglobin and delays death in NOD mice. Autoimmunity. 1998;28:157-161.
10. Wright RO, Lewander WJ, Woolf AD. Methemoglobinemia: etiology, pharmacology, and clinical management. Ann Emerg Med. 1999;34:646-656.
11. DeGowin RL. A review of the therapeutic and hemolytic effects of dapsone. Arch Intern Med. 1967;120:242-248.
12. Diwan SK, Sharma AK, Jain AP, Gupta OP, Jajoo UN. Dapsone induced methaemoglobinaemia. Indian J Lepr. 1991;63:103-105.
13. Magna LA, Beiguelman B. NADH-methemoglobin reductase and methemoglobinemia among leprosy patients. Int J Lep Other Mycobact Dis. 1984;52:475-481.
14. Tack CJ, Wetzels JF. Decreased HbA1c levels due to sulfonamide-induced hemolysis in two IDDM patients. Diabetes Care. 1996;19:775-776.
15. Bertholon M, Mayer A, Francina A, Thivolet CH. Interference of dapsone in HbA1c monitoring of a type I diabetic patient with necrobiosis lipoidica [letter]. Diabetes Care. 1994;17:1364.
16. Howey JE, Browning MC, Fraser CG. Assay of serum fructosamine that minimizes standardization and matrix problems: use to assess components of biological variation. Clin Chem. 1987;33(2 Pt 1):269-272.